Not finding it? Sign in to also search OpenAlex live.
-
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour2021 European Journal of Cancer article Medicine Gastrointestinal Tumor Research and Treatment Open access
Suzanne George, Ping Chi, Michael Charles Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, +11 more
31citations -
Abstract CT064: Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a phase 1 dose escalation study2024 Cancer Research conference-abstract Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism
Anne Bellon, Omar Saavedra, Ingrid M.E. Desar, Mathilde Jalving, Jourik A. Gietema, Carla van Herpen, +10 more
0citations -
A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC).2025 Journal of Clinical Oncology conference-abstract Medicine Radiopharmaceutical Chemistry and Applications
Andrei H. Iagaru, GIUSEPPE T. CARDACI, Aaron Richard Hansen, Jeffrey Y.C. Wong, Carlos Artigas, Karolien E. Goffin, +7 more
0citations -
Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.2021 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment
John Raymond Zalcberg, Michael Charles Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, César Serrano, +14 more
0citations -
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease2023 Journal of Crohn s and Colitis article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Archana Shubhakar, Bas C. Jansen, Alex T. Adams, Karli R. Reiding, Nicholas T. Ventham, Rahul Kalla, +8 more
20citations -
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors2020 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 1 patent
Aung Naing, Justin F. Gainor, Hans A. J. Gelderblom, Patrick M. Forde, Marcus Otho Butler, Chia‐Chi Lin, +11 more
86citations -
Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial2020 The Lancet Infectious Diseases article Immunology and Microbiology Parasites and Host Interactions Open access
Ayôla Akim Adégnika, Sophia G. de Vries, Yabo Josiane Honkpéhèdji, Jean Claude Dejon Agobe, Kafui G Vodonou, Rodrigue Bikangui, +24 more
57citations -
A phase I, randomized, double‐blind, placebo‐controlled, single‐ and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX‐128, a highly selective Nav1.8 inhibitor, in healthy adults
Hemme J. Hijma, Emilie M.J. van Brummelen, Pieter S. Siebenga, Geert Jan Groeneveld
19citations -
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial2024 The Lancet Infectious Diseases article Immunology and Microbiology Parasites and Host Interactions Open access
Jeannot Fréjus Zinsou, David Joseph Diemert, Jean Claude Dejon Agobe, Bayodé Roméo Adégbitè, Yabo Josiane Honkpéhèdji, Kafui G Vodonou, +12 more
17citations -
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study2022 British Journal of Clinical Pharmacology article Medicine SARS-CoV-2 and COVID-19 Research Open access
Manon L. M. Prins, Johan L. van der Plas, Maurits F. J. M. Vissers, Cécile L. Berends, Gaby Tresch, Marianne Soergel, +10 more
10citations -
476P First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors2022 Annals of Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 1 patent
F. A. L. M. Eskens, F. Opdam, E. Gort, H. Gelderblom, L. Prestegarden, C. Pico-Navarro
4citations -
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease2021 Research Square preprint Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Archana Shubhakar, Bas C. Jansen, Alex T. Adams, Karli R. Reiding, Nicholas T. Ventham, Rahul Kalla, +8 more
2citations -
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
Ulrike Anneliese Nitz, Oleg Gluz, Mathias Christgen, E.‐M. Grischke, Doris Augustin, Sherko Küemmel, +14 more
1citations -
SAT0104 MAINTENANCE OF SDAI REMISSION AND PATIENT-REPORTED OUTCOMES (PROS) FOLLOWING DOSE DE-ESCALATION OF ABATACEPT IN MTX-NAÏVE, ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+ PATIENTS WITH EARLY RA: RESULTS FROM AVERT-2, A RANDOMISED PHASE IIIB STUDY2020 Annals of the Rheumatic Diseases article Medicine Rheumatoid Arthritis Research and Therapies Open access
Paul E. Emery, Yoshiya Tanaka, Vivian P. Bykerk, Tom W. J. Huizinga, Gustavo Citera, C.O. Bingham, +8 more
1citations